Stocks News

LAST PRICE
50.0600
TODAY'S CHANGE (%)
Trending Up2.4400 (5.1239%)

Bid / Lots
48.6800/ 1
Ask / Lots
51.5000/ 10
Open / Previous Close
47.6300 / 47.6200
Day Range
Low 47.6300
High 51.3197
52 Week Range
Low 20.8400
High 51.3197
Volume
1,475,969
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 31, 2024
- DJ Corcept Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 7:28AM ET on Thursday Oct 31, 2024 by Dow Jones
  7:28AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 31, 2024 07:28 ET (11:28 GMT)
Oct 30, 2024
- -- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Posts Q3 EPS $0.41, from 4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires
  4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires
  Companies Mentioned: CORT
  04:37 PM EDT, 10/30/2024 (MT Newswires) -- ...
- Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  "Relacorilant has the potential to become the standard of care for patients with platinum-resistant ovarian cancer. If ROSELLA replicates the positive results of our large, controlled, Phase 2 study, it will constitute a major medical advance and serve as the basis for relacorilant's next NDA. We expect progression-free survival data, ROSELLA's primary endpoint, by the end of this year," said Dr. Guyer.
- *DJ Corcept Therapeutics 3Q EPS 41c >CORT, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  "Relacorilant has the potential to become the standard of care for patients with platinum-resistant ovarian cancer. If ROSELLA replicates the positive results of our large, controlled, Phase 2 study, it will constitute a major medical advance and serve as the basis for relacorilant's next NDA. We expect progression-free survival data, ROSELLA's primary endpoint, by the end of this year," said Dr. Guyer.
Oct 23, 2024
- Press Release: Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call, from 5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones
  5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
  REDWOOD CITY, Calif.--(BUSINESS WIRE)--October 23, 2024--
  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on October 30, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Today
- ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November, from 9 minutes ago by Dow Jones
  9 minutes ago by Dow Jones
  Companies Mentioned: ANIP
- Levi & Korsinsky Reminds Shareholders of an Investigation into Harmony Biosciences Holdings, Inc. (HRMY) Regarding Potential Securities Fraud Allegations, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: HRMY
Nov 1, 2024
- Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY, from 7:31AM ET on Friday Nov 01, 2024 by Dow Jones
  7:31AM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: HRMY
Oct 31, 2024
- Shareholder Rights Advocates at Levi & Korsinsky Investigate Harmony Biosciences Holdings, Inc. (HRMY) Regarding Possible Securities Fraud Violations, from 7:31AM ET on Thursday Oct 31, 2024 by Dow Jones
  7:31AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: HRMY
- HUTCHMED Earns $20 Million Milestone Payment After Takeda Reaches Over $200 Million in Fruquintinib Sales, from 5:52AM ET on Thursday Oct 31, 2024 by MT Newswires
  5:52AM ET on Thursday Oct 31, 2024 by MT Newswires
  Companies Mentioned: TAK, HCM
- Press Release: HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA(R) (fruquintinib) Sales by Takeda, from 4:30AM ET on Thursday Oct 31, 2024 by Dow Jones
  4:30AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: TAK, HCM
- HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA(R) (fruquintinib) Sales by Takeda, from 4:30AM ET on Thursday Oct 31, 2024 by Dow Jones
  4:30AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: TAK, HCM
Oct 30, 2024
- *DJ Harmony Biosciences Prices 8M Share Offering by Selling Shareholders at $31.00 Each >HRMY, from 10:35PM ET on Wednesday Oct 30, 2024 by Dow Jones
  10:35PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: HRMY
- Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders, from 10:30PM ET on Wednesday Oct 30, 2024 by PR Newswire
  10:30PM ET on Wednesday Oct 30, 2024 by PR Newswire
  Companies Mentioned: HRMY
- Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders, from 10:30PM ET on Wednesday Oct 30, 2024 by Dow Jones
  10:30PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: HRMY

Corcept Therapeutics Inc
NASDAQ:CORTUnited States

Search Criteria

Oct 31, 2024

DJ Corcept Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 7:28AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 30, 2024

-- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Posts Q3 EPS $0.41, from 4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones

*DJ Corcept Therapeutics 3Q EPS 41c >CORT, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones

Oct 23, 2024

Press Release: Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call, from 5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones

Peers Headlines

Today

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November, from 9 minutes ago by Dow Jones

Levi & Korsinsky Reminds Shareholders of an Investigation into Harmony Biosciences Holdings, Inc. (HRMY) Regarding Potential Securities Fraud Allegations, from 9 hours ago by Dow Jones

Nov 1, 2024

Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY, from 7:31AM ET on Friday Nov 01, 2024 by Dow Jones

Oct 31, 2024

Shareholder Rights Advocates at Levi & Korsinsky Investigate Harmony Biosciences Holdings, Inc. (HRMY) Regarding Possible Securities Fraud Violations, from 7:31AM ET on Thursday Oct 31, 2024 by Dow Jones

HUTCHMED Earns $20 Million Milestone Payment After Takeda Reaches Over $200 Million in Fruquintinib Sales, from 5:52AM ET on Thursday Oct 31, 2024 by MT Newswires

Press Release: HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA(R) (fruquintinib) Sales by Takeda, from 4:30AM ET on Thursday Oct 31, 2024 by Dow Jones

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA(R) (fruquintinib) Sales by Takeda, from 4:30AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 30, 2024

*DJ Harmony Biosciences Prices 8M Share Offering by Selling Shareholders at $31.00 Each >HRMY, from 10:35PM ET on Wednesday Oct 30, 2024 by Dow Jones

Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders, from 10:30PM ET on Wednesday Oct 30, 2024 by PR Newswire

Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders, from 10:30PM ET on Wednesday Oct 30, 2024 by Dow Jones